Display options
Cite
Höfer T, Krichevsky O, Altan-Bonnet G. Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol. 2012;3:268doi: 10.3389/fimmu.2012.00268.
Höfer, T., Krichevsky, O., & Altan-Bonnet, G. (2012). Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Frontiers in immunology, 3268. https://doi.org/10.3389/fimmu.2012.00268
Höfer, Thomas, et al. "Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses." Frontiers in immunology vol. 3 (2012): 268. doi: https://doi.org/10.3389/fimmu.2012.00268
Höfer T, Krichevsky O, Altan-Bonnet G. Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol. 2012 Sep 05;3:268. doi: 10.3389/fimmu.2012.00268. eCollection 2012. PMID: 22973270; PMCID: PMC3433682.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2012 Sep 05;3:268. doi: 10.3389/fimmu.2012.00268. eCollection 2012.

Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses.

Frontiers in immunology

Thomas Höfer, Oleg Krichevsky, Grégoire Altan-Bonnet

Affiliations

  1. Division of Theoretical Systems Biology, German Cancer Research Center Heidelberg, Germany.

PMID: 22973270 PMCID: PMC3433682 DOI: 10.3389/fimmu.2012.00268

Abstract

In this review we discuss how the competition for cytokines between different cells of the immune system can shape the system wide immune response. We focus on interleukin-2 (IL-2) secretion by activated effector T cells (T(eff)) and on the competition for IL-2 consumption between T(eff) and regulatory T cells (T(reg)). We discuss the evidence for the mechanism in which the depletion of IL-2 by T(reg) cells would be sufficient to suppress an autoimmune response, yet not strong enough to prevent an immune response. We present quantitative estimations and summarize our modeling effort to show that the tug-of-war between T(reg) and T(eff) cells for IL-2 molecules can be won by T(reg) cells in the case of weak activation of T(eff) leading to the suppression of the immune response. Or, for strongly activated T(eff) cells, it can be won by T(eff) cells bringing about the activation of the whole adaptive immune system. Finally, we discuss some recent applications attempting to achieve clinical effects through the modulation of IL-2 consumption by T(reg) compartment.

Keywords: IL-2; computational modeling; cytokine competition; regulatory T cells; systems immunology

References

  1. Int Immunol. 1998 Dec;10(12):1969-80 - PubMed
  2. Immunology. 2008 May;124(1):13-22 - PubMed
  3. J Exp Med. 1998 Jul 20;188(2):287-96 - PubMed
  4. Science. 1993 Nov 12;262(5136):1059-61 - PubMed
  5. J Biol Chem. 1991 Jan 25;266(3):1497-501 - PubMed
  6. J Immunol. 2007 Apr 1;178(7):4062-71 - PubMed
  7. Nat Med. 2001 Jan;7(1):114-8 - PubMed
  8. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3058-63 - PubMed
  9. J Exp Med. 2009 Apr 13;206(4):751-60 - PubMed
  10. Nat Immunol. 2007 Dec;8(12):1353-62 - PubMed
  11. J Immunol. 2003 Jan 1;170(1):394-9 - PubMed
  12. J Exp Med. 2001 Sep 3;194(5):629-44 - PubMed
  13. Eur J Immunol. 2008 Jun;38(6):1643-53 - PubMed
  14. Science. 1998 Mar 27;279(5359):2118-21 - PubMed
  15. J Exp Med. 2002 Jul 15;196(2):247-53 - PubMed
  16. Front Immunol. 2012 May 25;3:125 - PubMed
  17. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8886-91 - PubMed
  18. Mol Syst Biol. 2010 Nov 30;6:437 - PubMed
  19. Eur J Immunol. 2004 Sep;34(9):2480-8 - PubMed
  20. Eur J Immunol. 2005 May;35(5):1336-41 - PubMed
  21. Immunity. 2011 Mar 25;34(3):422-34 - PubMed
  22. Mol Syst Biol. 2010 Apr 13;6:359 - PubMed
  23. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7529-34 - PubMed
  24. Science. 2010 Jun 11;328(5984):1404-8 - PubMed
  25. Nature. 2006 Jun 15;441(7095):890-3 - PubMed
  26. Immunity. 2011 Mar 25;34(3):409-21 - PubMed
  27. J Theor Biol. 2006 Jul 7;241(1):134-41 - PubMed
  28. Immunol Rev. 1995 Dec;148:35-44 - PubMed
  29. PLoS One. 2007 Sep 26;2(9):e935 - PubMed
  30. Immunity. 2002 Aug;17(2):167-78 - PubMed
  31. J Cell Biol. 1995 Apr;129(1):55-64 - PubMed
  32. Semin Immunol. 2011 Dec;23(6):424-30 - PubMed
  33. Nat Immunol. 2007 Dec;8(12):1285-7 - PubMed
  34. Nat Immunol. 2010 Jun;11(6):520-6 - PubMed
  35. Immunity. 2009 May;30(5):636-45 - PubMed
  36. J Biol Chem. 1986 Nov 25;261(33):15450-4 - PubMed
  37. J Exp Med. 2005 Sep 19;202(6):793-804 - PubMed
  38. J Exp Med. 2007 Aug 6;204(8):1787-801 - PubMed
  39. Nat Med. 2012 Feb 06;18(2):208-9 - PubMed
  40. Immunity. 2008 May;28(5):687-97 - PubMed
  41. J Exp Med. 2006 Apr 17;203(4):1045-54 - PubMed
  42. Novartis Found Symp. 1998;215:200-11; discussion 211-30 - PubMed
  43. J Biol Chem. 1988 Sep 15;263(26):12860-5 - PubMed
  44. J Immunol. 1995 Aug 1;155(3):1151-64 - PubMed
  45. N Engl J Med. 2011 Dec 1;365(22):2055-66 - PubMed
  46. J Immunol. 2005 Dec 1;175(11):7274-80 - PubMed
  47. J Immunol. 2004 May 15;172(10):5973-9 - PubMed
  48. Biophys J. 2011 Nov 16;101(10):2360-9 - PubMed
  49. Int Immunol. 2005 Mar;17(3):279-88 - PubMed
  50. Nat Immunol. 2005 Nov;6(11):1142-51 - PubMed

Publication Types